Share Email Print

Journal of Biomedical Optics

Effect of antiangiogenic therapy on luciferase activity in a cytomegalovirus- or HSP70-promoter-transfected M21 tumor model
Author(s): Walter Hundt; Samira Guccione; Andreas Kiessling; Mykhaylo Burbelko; Christian Schink; Silke Steinbach; Caitlin E. O'Connell-Rodwell; Damiano Librizzi
Format Member Price Non-Member Price
PDF $20.00 $25.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

We investigated the effect of targeted gene therapy on heat shock protein 70 expression (Hsp70) and protein production (HSP70) in a melanoma tumor model (M21; M21-L). M21 and M21-L cells transfected with a plasmid containing the Hsp70 (Hspa1b) or the cytomegalovirus (CMV) promoter and the luciferase reporter gene were injected into mice; the resulting tumors grew to a size of 650  mm3. Mice (five per group) were intravenously treated with an Arg-Gly-Asp peptide-nanoparticle/Raf-1 kinase inhibitor protein complex [RGD-NP/RAF(-)] or with a nanoparticle control. Bioluminescence imaging (IVIS®, Xenogen, USA) was performed at 12, 24, 48, and 72 h after the treatment cycle. Western blot analysis of HSP70 protein was performed to monitor protein expression. The size of the treated M21 tumors remained fairly constant (647.8±103.4  mm2 at the beginning versus 704.8±94.4  mm3 at the end of the experiment). The size of the M21-L tumors increased, similar to the untreated control tumors. Bioluminescent imaging demonstrated that when transcription was controlled by the CMV promoter, luciferase activity decreased to 17.9%±4.3% of baseline values in the treated M21 tumors. When transcription was controlled by the Hsp70 promoter, the highest luciferase activity (4.5±0.7-fold increase over base-line values) was seen 24 h after injection in the M21 tumors; however, no luciferase activity was seen in the M21-L tumors. In accordance with bioluminescent imaging, western blot analysis showed a peak in HSP70 production at 24 h after the injection of the RGD-NP/RAF(-) complex in the M21 tumors; however, no HSP70 protein induction was seen in the M21-L tumors. Thus, targeted antiangiogenic therapy can induce Hsp70 expression and HSP70 protein in melanoma tumors.

Paper Details

Date Published: 5 June 2012
PDF: 8 pages
J. Biomed. Opt. 17(6) 065001 doi: 10.1117/1.JBO.17.6.065001
Published in: Journal of Biomedical Optics Volume 17, Issue 6
Show Author Affiliations
Walter Hundt, Stanford Univ. School of Medicine (United States)
Samira Guccione, Stanford Univ. School of Medicine (United States)
Andreas Kiessling, Philipps-Univ. Marburg (Germany)
Mykhaylo Burbelko, Philipps-Univ. Marburg (Germany)
Christian Schink, Philipps-Univ. Marburg (Germany)
Silke Steinbach, Philipps-Univ. Marburg (Germany)
Caitlin E. O'Connell-Rodwell, Stanford Univ. School of Medicine United (United States)
Damiano Librizzi, Philipps-Univ. Marburg (Germany)

© SPIE. Terms of Use
Back to Top